ABSTRACT
INTRODUCTION
Interest in hypofractionation for adjuvant breast radiotherapy re-emerged in the mid1980s after re-analysis of historical data, using the linear-quadratic model, suggested that breast cancer is as sensitive to fraction size as the dose-limiting late responding normal tissues [1, 2] . Two prospective randomised trials subsequently reported results consistent with this suggestion, including the Royal Marsden NHS Foundation Trust/Gloucestershire Oncology Centre (RMH/GOC) trial, which tested two dose levels of a 13-fraction regimen over 5 weeks against 50 Gy in 25 fractions, and the Ontario trial, which tested a 16-fraction regimen over 3.2 weeks against 50 Gy in 25 fractions [3] [4] [5] . Subsequently, the UK Standardisation of Breast Radiotherapy (START) Trials tested two 13-fraction schedules over 5 weeks and 40 Gy in 15 fractions over 3 weeks, each against 50 Gy in 25 fractions over 5 weeks. The 5-year results of the START Trial are also consistent with the hypothesis that breast cancer has a comparable sensitivity to fraction size as the late responding normal tissues of the breast [6] . If true, it means that the current use of small fraction sizes spares the tumour as effectively as the late responding normal tissues.
Thirteen-, 15-or 16-fraction schedules are unlikely to represent the limits of hypofractionation. To explore this further, the UK National Cancer Research Network (NCRN) FAST trial randomised 900 patients to 5 fractions of 5.7 Gy or 6.0 Gy delivered in 5 weeks versus 25 fractions of 2.0 Gy with late adverse effects as primary endpoints [7] . The FAST Trial is currently in follow-up. In preparation for a future phase III randomised trial of a 5-fraction regimen delivered in 5 days, a pilot study evaluated erythema and moist desquamation in patients receiving 30 Gy in 5 fractions delivered twice-weekly to the whole breast in 15 days. The early results of this experience are reported here.
METHODS

Patients
Patients eligible for entry into this pilot study were women aged ≥ 50 years following breast conservation surgery for invasive breast carcinoma with pathological tumour size < 3 cm, complete microscopic resection, no lymphovascular invasion, negative axillary node status and no requirement for neoadjuvant or adjuvant cytotoxic therapy.
Radiotherapy
Patients were treated in the supine position, with both arms abducted at 90º. The reproducibility of positioning was verified by orthogonal laser beams. The planning target volume was defined as the entire breast with a 1 cm margin to palpable breast tissue. The reference point for dose prescription was chosen according to International Commission on Radiation Units (ICRU 50) guidelines. Dose homogeneity complied with ICRU 50 recommendations. Full dose compensation was delivered using multiple static fields [8] if the maximum dose was > 105%.
Megavoltage 6 or 10 MV photons were used in all patients. No tumour bed boost was delivered to any patient.
Assessment of normal tissue reactions
Clinical assessments of early normal tissue reaction were performed once-weekly during radiotherapy and for five weeks after the end of treatment (7 weeks overall).
These recorded degree of erythema and moist desquamation on 4-point graded scales (grade 0 = none, 1 = mild, 2 = moderate, 3 = severe) on case report forms.
The maximum orthogonal dimensions of moist desquamation were also recorded.
Patients consented to have frontal photographs taken of their breasts prior to radiotherapy and 2 years post-treatment under standard conditions. Pairs of photographs were taken, one with both arms on hips and a second with both arms raised above the head. Additional photographs were also collected in selected patients with acute skin reactions > grade 2 erythema. Change of breast appearance compared with the baseline pre-radiotherapy photographs was scored on a 3-point graded scale (0 = no change, 1 = mild change, 2 = marked change) by two observers (LG and JY). Breast size was also assessed from the baseline photographs on a 3-point scale (small, medium, large).
Statistical methods
The sample size for this pilot study was chosen to be 30 patients on grounds of feasibility rather than statistical considerations. Considering a rate of moist desquamation < 20%, this sample size is associated with a standard error ≤ 7%. The percentages of patients experiencing erythema and moist desquamation and change in breast appearance (photographic) at 2 years were calculated with exact 95% confidence intervals (CI). From the baseline photographs, breast size was recorded as small in 14 (46.7%), medium in 13 (43.3%) and large in 3 (10%) women. There was some evidence that risk of acute skin reactions and change in breast appearance (photographic) increased with larger breast size, but the small sample size prevented formal statistical testing, see Table 1 .
RESULTS
Written
DISCUSSION
The early and 2-year normal tissue responses scored in this pilot study were generally very mild, and not different to those expected after standard regimens. A reliable comparison of these effects following 30 Gy in 5 fractions over 15 days with the effects of 50 Gy in 25 fractions is limited by the lack of a randomised comparator group. An RTOG (97-13) trial testing supportive care of skin toxicity in women undergoing breast radiotherapy, combined with results of prior RTOG experience, reported 7% grade 0, 58% grade 1, 32% grade 2, 3% grade 3, and no grade 4 acute skin toxicity [9] . Retrospective re-grading of skin reactions in the present pilot study, applying RTOG criteria, produced comparable rates: 3% grade 0, 67% grade 1, 30% grade 2 and no grade 3 or 4 toxicity. However, differences in breast size and radiation dosimetry limit the reliability of this comparison [10, 11] . A correlation between breast size and acute toxicity was reported in the RTOG 97-13 study, with small-breasted women developing 11 -21% Grade 2 or higher skin toxicity compared to 43 -50% in large-breasted women. There was some evidence of a similar association between acute and late toxicity and breast size in the pilot study, but numbers were too small for formal statistical testing.
Changes in breast appearance two years after treatment were very mild, and comparable with the 2-year rates reported after 50 Gy in 25 fractions in the RMH/GOC and START trials [3, 6] . However, the same limitations apply to this comparison as discussed for acute skin toxicities. In addition, the 9 (30%) patients in the pilot study treated with full (3D) dose compensation may have developed slightly lower levels of late normal tissue effects than if standard 2D dosimetry had been used [10, 11] . Late changes in normal tissues are also more sensitive to fraction size than early skin reactions [12] . A meta-analysis of the RMH/GOC and NCRI START trials generated an α/β value of 3.4 Gy for late adverse effects, making the present dose schedule equivalent to a total dose of 52 Gy in 2.0 Gy fractions. This estimate assumes complete repair between fractions, whereas it is clear that this is incomplete in human skin even after 24 hours [13] . If an incomplete repair model is applied, 30 Gy in 5 fractions over 5 days is expected to be equivalent to 50 Gy in 2.0 Gy fractions
The long-term aim is to explore a whole breast radiotherapy schedule of 5 fractions delivered in 5 days. It is not expected that reducing overall treatment time from 15 to 5 days will enhance acute skin reactions, since accelerated repopulation in basal epidermis starts only after 15 days [15] . Where late effects are concerned, a randomised trial is needed to compare 5-day schedules against 50 Gy in 25 fractions.
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